Videos

Binod Dhakal, MD, MS, discusses the safety and efficacy findings from the CARTITUDE-4 trial.

Binod Dhakal, MD, MS, provides an overview of the CARTITUDE-4 trial, including its methods, design, and inclusion criteria.

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Erika Hamilton, MD, discusses the different classes of endocrine therapies and how they compare to one another.

Joshua K. Sabari, MD, discusses the unique mechanism of action of B7-H3, highlighting its role as an immune checkpoint regulator that is overexpressed in SCLC and associated with poor prognosis. He notes that B7-H3 blockade can enhance CD8-positive T-cell activity and may serve as a promising treatment option for SCLC that has progressed after platinum-based chemotherapy.

Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.

Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.

Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy for patients with ES-SCLC, highlighting that statistically significant trial end points, such as improved PFS and OS, could encourage community oncologists to adopt this dual maintenance approach.

Mark R. Litzow, MD, discusses the methods and design used in the ECOG-ACRIN E1910 trial.

Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.

Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.

Erika Hamilton, MD, discusses some of the most promising endocrine therapies in breast cancer.

Jacob Stein, MD, MPH, discusses how nab-sirolimus improves outcomes for patients with advanced perivascular epithelioid cell tumors compared with other treatments or no treatment options.

Ticiana Leal, MD, discusses how ifinatamab deruxtecan, a B7-H3 antibody-drug conjugate, targets the overexpressed B7-H3 in extensive-stage small cell lung cancer (ES-SCLC) to potentially enhance immune response and improve clinical outcomes, as highlighted by efficacy results from the Phase 1/ 2 IDeate-Lung02 study, which reported a 52.4% objective response rate and a 12.2-month overall survival (OS).

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.

Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.

Tanya Gupta, MD, evaluates fam-trastuzumab deruxtecan-nxki and its role in breast cancer treatment.

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer.

Joshua K. Sabari, MD, discusses the future treatment potential of tarlatamab as a combination therapy with other anticancer agents for previously treated SCLC, suggesting that it could enhance efficacy and improve patient outcomes following 2 or more lines of prior therapy.

Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.

Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study assessed the sensitivity and specificity of a cell-free DNA epigenomic assay in R0 stage II to III CRC, emphasizing the importance of monitoring minimal MRD to inform treatment decisions and the critical lead time between ctDNA positivity and radiographic disease recurrence.

Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).

Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.

Joshua K. Sabari, MD, discusses the expected PFS of 3 to 6 months and OS of 6 to 12 months for second- or third-line therapy in previously treated patients with relapsed/refractory SCLC.

Robert L. Ferris, MD, PhD, highlights groundbreaking advancements presented at the recent World Congress on Lung Cancer held in San Diego, California.

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

Sergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.